Найти в Дзене

Cancer mortality has increased in every third region of Russia

In 30 of 85 regions of Russia in 2017 increased cancer mortality, reports RBC, citing the monitoring of the All-Russia People's Front (ONF) and the fund "Health". The largest increase in mortality was recorded in the Magadan region (7.7%), Dagestan (7.2%), Bashkiria (6.9%), Kalmykia (6.8) and Sevastopol (6.5%). In the whole country, the death rate from cancer has decreased over the year by 2.4%. The number of newly diagnosed cancer increased by 3%. Onf experts believe that this indicates an increase in diagnostic efficiency. Most detection increased in the Chukotka Autonomous region (33.1%), Khabarovsk territory (14.2%), Amur region (11.5%), Crimea (9%) and Chuvashia (8.5%). The worst situation with cancer detection in 2017 was recorded in Kalmykia and Yakutia, where cancer in the last stages is diagnosed in 53% and 52.6% of cases, respectively. In general, in 2017, the ratio of cancer diseases that doctors identified in the early and late stages was 55.6% to 39%. In 2016, these figure

In 30 of 85 regions of Russia in 2017 increased cancer mortality, reports RBC, citing the monitoring of the All-Russia People's Front (ONF) and the fund "Health". The largest increase in mortality was recorded in the Magadan region (7.7%), Dagestan (7.2%), Bashkiria (6.9%), Kalmykia (6.8) and Sevastopol (6.5%).

In the whole country, the death rate from cancer has decreased over the year by 2.4%. The number of newly diagnosed cancer increased by 3%. Onf experts believe that this indicates an increase in diagnostic efficiency. Most detection increased in the Chukotka Autonomous region (33.1%), Khabarovsk territory (14.2%), Amur region (11.5%), Crimea (9%) and Chuvashia (8.5%). The worst situation with cancer detection in 2017 was recorded in Kalmykia and Yakutia, where cancer in the last stages is diagnosed in 53% and 52.6% of cases, respectively.

In general, in 2017, the ratio of cancer diseases that doctors identified in the early and late stages was 55.6% to 39%. In 2016, these figures were 54.7% and 39.6% respectively.

Earlier, representatives of patient organizations of cancer patients said that in Russia there are problems with the availability of innovative drugs. Often, patients receive new drugs only ten years after entering the international market.